Breaking News

Lonza Expands Cocoon Platform with Magnetic Cell Selection Capabilities

New functionality strengthens the Cocoon Platform’s role in the commercialization of cell therapies, helping to advance discoveries into the clinic.

Author Image

By: Charlie Sternberg

Associate Editor

Lonza, a global cell and gene therapy manufacturer, has expanded the functionality of its Cocoon Platform for automated cell therapy manufacturing. The new Magnetic Selection adds capabilities in cell binding, cell separation, and bead removal (if required), all implemented within the Cocoon cassette.   The capability is being launched in April 2022 and is available in Lonza’s new Magnetic Selection cassettes. Magnetic Cell Separation The consistency and quality of cell therapy products r...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters